文献速递毛发、甲与色素性疾病

外用托法替布与外用他克莫司治疗局限性白癜风的疗效比较:随机研究者盲法个体内试验

Comparative efficacy of topical tofacitinib versus topical tacrolimus in the treatment of localized vitiligo: a randomized investigator-blinded intraindividual trial.
PubMed 文献 · Br J Dermatol · 2025-01-01

该研究为16周前瞻性随机研究者盲法个体内单中心比较试验,纳入30例稳定期非节段性白癜风患者共60处对称皮损,分别外用托法替布2%软膏或他克莫司0.1%软膏每日两次。主要结局为达到治疗成功(VNS评分4或5)的皮损百分比,托法替布组47%(14/30)与他克莫司组37%(11/30)相比差异无统计学意义(P=0.60)。

要点

  • 外用托法替布2%软膏治疗局限性白癜风疗效与他克莫司0.1%软膏相当,差异无统计学意义。
  • 托法替布组达到治疗成功的中位时间8周,短于他克莫司组的12周,但差异无统计学意义。
  • 托法替布组不良事件2例,少于他克莫司组的7例,安全性趋势更优。

核心结论

  • 外用托法替布治疗局限性白癜风疗效与他克莫司相当,但患者报告缓解更早且安全性趋势更优,需更大样本验证。

研究设计与样本

  • 前瞻性随机研究者盲法个体内单中心比较试验,2024年1月至12月开展,共16周。
  • 纳入30例缓慢进展的非节段性白癜风患者,受累面积≤5%体表面积,共60处对称皮损。
  • 皮损随机分配至外用托法替布2%软膏或他克莫司0.1%软膏,每日两次,持续16周。
  • 主要结局为达到治疗成功(VNS评分4或5)的皮损百分比。

主要发现

  • 托法替布组47%(14/30)皮损达到治疗成功,他克莫司组37%(11/30),P=0.60。
  • 托法替布组达到治疗成功的中位时间8周(95%CI 4.333-11.667),他克莫司组12周(95%CI 8.301-15.699),P=0.18。
  • 托法替布组33%(10处)和他克莫司组20%(6处)皮损实现>80%复色。
  • 托法替布组不良事件2例,他克莫司组7例。
  • 两种治疗均显示面部皮损疗效优于肢端或躯干皮损。

关键数值与推荐

  • 治疗成功定义为白癜风显著度量表(VNS)评分4(明显更不明显)或5(不再明显)。
  • 复色程度评估中>80%复色为显著复色指标。

临床怎么用

  • 外用托法替布2%软膏可作为局限性白癜风的治疗选择,尤其适用于早期或局限皮损。
  • 面部皮损对两种治疗应答均优于肢端和躯干皮损,治疗时需考虑部位差异。
  • 托法替布可能提供更早的患者报告缓解和更少不良事件,但需结合个体情况选择。

局限性

  • 样本量较小(30例患者60处皮损),需更大样本研究验证趋势性发现。
  • 研究为单中心设计,随访16周,长期疗效和安全性未评估。
  • 主要结局差异无统计学意义,趋势性结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topical ruxolitinib was recently approved by the US Food and Drug Administration for the treatment of vitiligo. Studies comparing other topical Janus kinase inhibitors with established topical therapies like tacrolimus are lacking. OBJECTIVES: To compare the efficacy and tolerability of topical tofacitinib and topical tacrolimus in patients with localized vitiligo using patient- and investigator-reported outcome measures. METHODS: This was a prospective randomized investigator-blinded intraindividual single-centre comparative trial conducted over 16 weeks between January and December 2024. Thirty patients with 60 symmetrical vitiligo patches were enrolled. Eligible participants had slowly spreading, nonsegmental vitiligo affecting ≤ 5% of their body surface area. Patches were randomized to receive either topical tofacitinib 2% ointment or topical tacrolimus 0.1% ointment twice daily for 16 weeks. The primary outcome was percentage of patches achieving treatment success, defined as a Vitiligo Noticeability Scale (VNS) score of 4 ('a lot less noticeable') or 5 ('no longer noticeable'). Secondary outcomes included time to treatment success, trends of VNS among groups, extent of repigmentation and adverse effects. The study was registered with the Clinical Trial Registry of India (CTRI/2023/12/060431). RESULTS: Of the patches treated with tofacitinib, 47% (n = 14/30) achieved treatment success vs. 37% (n = 11/30) of those treated with tacrolimus (P = 0.60). The median time to treatment success was shorter for patches treated with tofacitinib [8 weeks; 95% confidence interval (CI) 4.333-11.667] than for those treated with tacrolimus [12 weeks; 95% CI 8.301-15.699 (P = 0.18)]. Significant repigmentation was seen with both treatments, with 33% (n = 10) of tofacitinib-treated patches and 20% (n = 6) of those treated with tacrolimus achieving > 80% repigmentation. There were fewer adverse events with tofacitinib (n = 2) than with tacrolimus (n = 7). Facial lesions responded better than acral or trunk lesions with both treatments. CONCLUSIONS: Topical tofacitinib demonstrated comparable efficacy to tacrolimus for localized vitiligo but showed trends toward earlier patient-reported response and a more favourable safety profile, a finding that could be validated in future studies with larger sample sizes. Vitiligo is a persistent or chronic condition in which areas of skin lose their normal pigment (colour) and become very pale, white or light pink. Vitiligo is common, affecting about 1%, or 1 in 100 people, of the world’s population. The condition can significantly affect a person’s psychological well-being and quality of life. Although vitiligo cannot be cured, some treatments can stop it from spreading and help the skin regain its colour. In this study, we compared two ointments. One is called ‘tacrolimus’ (which is commonly used) and the other is ‘tofacitinib’ (a newer option). We did this to see which worked better for treating small areas of vitiligo that were actively spreading. We focused on 30 people who had symmetrical patches of vitiligo and monitored them for 16 weeks. One side of their body was treated with tacrolimus, and the other with tofacitinib. We did this so that we could directly compare the two treatments. We looked at how visible the white patches were after treatment, how much colour came back and how well the new skin matched the surrounding area. We also recorded any side effects. We found that tofacitinib showed slightly better results in terms of how noticeable the patches were by the end of the study. Both ointments were well tolerated and safe. Our findings suggest that tofacitinib ointment might be a useful new option for people with early or limited vitiligo. As tofacitinib works by targeting the immune system in the skin, it offers a different approach from traditional treatments. It could help more people with vitiligo get effective and safe relief from their symptoms.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Mehta H, Bishnoi A, Vinay K, et al. Comparative efficacy of topical tofacitinib versus topical tacrolimus in the treatment of localized vitiligo: a randomized investigator-blinded intraindividual trial. Br J Dermatol. 2025. PMID: 40758816. doi:10.1093/bjd/ljaf306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。